Works matching IS 0344-5704 AND VI 67 AND IP 2 AND DT 2011
Results: 29
Chemotherapeutic activity of silymarin combined with doxorubicin or paclitaxel in sensitive and multidrug-resistant colon cancer cells.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 2, p. 369, doi. 10.1007/s00280-010-1335-8
- By:
- Publication type:
- Article
Pharmacokinetics in mice and metabolism in murine and human liver fractions of the putative cancer chemopreventive agents 3',4',5',5,7-pentamethoxyflavone and tricin (4',5,7-trihydroxy-3',5'-dimethoxyflavone).
- Published in:
- 2011
- By:
- Publication type:
- journal article
Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients.
- Published in:
- 2011
- By:
- Publication type:
- journal article
In vitro anti-mesothelioma activity of cisplatin-gemcitabine combinations: evidence for sequence-dependent effects.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 2, p. 265, doi. 10.1007/s00280-010-1314-0
- By:
- Publication type:
- Article
Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 2, p. 249, doi. 10.1007/s00280-010-1311-3
- By:
- Publication type:
- Article
Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of human aminopeptidase N.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 2, p. 381, doi. 10.1007/s00280-010-1333-x
- By:
- Publication type:
- Article
Pharmacokinetics in mice and metabolism in murine and human liver fractions of the putative cancer chemopreventive agents 3′,4′,5′,5,7-pentamethoxyflavone and tricin (4′,5,7-trihydroxy-3′,5′-dimethoxyflavone).
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 2, p. 255, doi. 10.1007/s00280-010-1313-1
- By:
- Publication type:
- Article
Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 2, p. 349, doi. 10.1007/s00280-010-1323-z
- By:
- Publication type:
- Article
Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 2, p. 339, doi. 10.1007/s00280-010-1327-8
- By:
- Publication type:
- Article
A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 2, p. 447, doi. 10.1007/s00280-010-1346-5
- By:
- Publication type:
- Article
Risk factors contributing to the development of carboplatin-related delayed hypersensitivity reactions in Japanese patients with gynecologic cancers.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 2, p. 415, doi. 10.1007/s00280-010-1338-5
- By:
- Publication type:
- Article
Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 2, p. 421, doi. 10.1007/s00280-010-1337-6
- By:
- Publication type:
- Article
A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 2, p. 431, doi. 10.1007/s00280-010-1328-7
- By:
- Publication type:
- Article
Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 2, p. 439, doi. 10.1007/s00280-010-1344-7
- By:
- Publication type:
- Article
A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).
- Published in:
- 2011
- By:
- Publication type:
- Report
Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 2, p. 475, doi. 10.1007/s00280-010-1450-6
- By:
- Publication type:
- Article
The role of K-Ras gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cell lines.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 2, p. 481, doi. 10.1007/s00280-010-1463-1
- By:
- Publication type:
- Article
Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine) in cancer patients.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 2, p. 393, doi. 10.1007/s00280-010-1331-z
- By:
- Publication type:
- Article
Phase I study of the combination of nedaplatin and gemcitabine in previously untreated advanced squamous cell lung cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 2, p. 325, doi. 10.1007/s00280-010-1321-1
- By:
- Publication type:
- Article
Schedule treatment design and quantitative in vitro evaluation of chemotherapeutic combinations for metastatic prostate cancer therapy.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 2, p. 275, doi. 10.1007/s00280-010-1315-z
- By:
- Publication type:
- Article
Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 2, p. 331, doi. 10.1007/s00280-010-1325-x
- By:
- Publication type:
- Article
Announcement.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 2, p. 247, doi. 10.1007/s00280-011-1564-5
- Publication type:
- Article
A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 2, p. 315, doi. 10.1007/s00280-010-1320-2
- By:
- Publication type:
- Article
Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors.
- Published in:
- 2011
- By:
- Publication type:
- Report
Second-line chemotherapy with Capecitabine (Xeloda) and Docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 2, p. 361, doi. 10.1007/s00280-010-1329-6
- By:
- Publication type:
- Article
Combination effects of platinum drugs and N, N diethylnorspermine on spermidine/spermine N-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 2, p. 401, doi. 10.1007/s00280-010-1334-9
- By:
- Publication type:
- Article
Tamoxifen and raloxifene suppress the proliferation of estrogen receptor-negative cells through inhibition of glutamine uptake.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 2, p. 285, doi. 10.1007/s00280-010-1316-y
- By:
- Publication type:
- Article
Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 2, p. 305, doi. 10.1007/s00280-010-1318-9
- By:
- Publication type:
- Article
A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 2, p. 293, doi. 10.1007/s00280-010-1319-8
- By:
- Publication type:
- Article